E330034G19Rik Inhibitors
E330034G19Rik, positioned upstream of or within the positive regulation of the proteasomal ubiquitin-dependent protein catabolic process, emerges as a pivotal player in cellular protein homeostasis. Its dual localization in the cytoplasm and nucleus signifies a multifaceted role in orchestrating the degradation of ubiquitinated proteins. The gene's specific expression in oocyte and ovary points to potential regulatory functions during crucial stages of cellular development and reproductive processes.
In the realm of inhibition, a diverse array of chemicals has been explored to modulate E330034G19Rik's activity, with a primary focus on disrupting the positive regulation of the proteasomal ubiquitin-dependent protein catabolic process. Direct inhibitors such as Bortezomib and Carfilzomib act by impeding the proteasomal activity, hindering the degradation of ubiquitinated proteins and subsequently impacting E330034G19Rik's regulatory role. Indirect inhibitors like MLN4924 and CAY10566 influence E330034G19Rik by targeting the NEDD8-activating enzyme and Nrf2-Keap1 interaction, respectively, leading to alterations in the cellular environment and affecting the gene's involvement in ubiquitin-dependent protein catabolism. These intricate mechanisms of inhibition highlight the interconnected pathways and processes through which E330034G19Rik exerts its regulatory influence, offering insights into potential strategies for precise modulation of its functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Inhibits the proteasomal ubiquitin-dependent protein catabolic process upstream of E330034G19Rik. MG-132 disrupts the proteasomal degradation machinery, leading to the accumulation of ubiquitinated proteins and inhibiting E330034G19Rik's positive regulation of this process. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Direct inhibitor of the proteasome, impacting E330034G19Rik by preventing the ubiquitin-dependent protein catabolic process. Bortezomib disrupts proteasomal activity, inhibiting the degradation of ubiquitinated substrates and interfering with E330034G19Rik's regulatory role. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits NEDD8-activating enzyme (NAE), indirectly impacting E330034G19Rik. MLN4924 prevents the neddylation process, leading to the inactivation of cullin-RING ligases (CRLs) and subsequently affecting E330034G19Rik's role in proteasomal ubiquitin-dependent degradation. | ||||||
CAY 10566 | 944808-88-2 | sc-205109 sc-205109A sc-205109B | 1 mg 5 mg 25 mg | $117.00 $512.00 $1527.00 | 4 | |
Disrupts the Nrf2-Keap1 interaction, influencing E330034G19Rik indirectly. CAY10566 activates the Nrf2 pathway, leading to increased expression of proteasomal subunits, modulating E330034G19Rik's positive regulation of the ubiquitin-dependent protein catabolic process. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Direct proteasome inhibitor, affecting E330034G19Rik by blocking ubiquitin-dependent protein degradation. Carfilzomib hinders the proteasomal activity, leading to the accumulation of ubiquitinated proteins and disrupting the positive regulation of this process by E330034G19Rik. | ||||||
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
Inhibits the NEDD8-activating enzyme, indirectly influencing E330034G19Rik. MLN7243 prevents neddylation, resulting in the inactivation of CRLs and modulating E330034G19Rik's role in positive regulation of the proteasomal ubiquitin-dependent protein catabolic process. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Disrupts the NF-κB pathway, indirectly influencing E330034G19Rik. Bay 11-7082 inhibits NF-κB activation, impacting the expression of proteasomal subunits and consequently affecting E330034G19Rik's role in positive regulation of ubiquitin-dependent protein catabolism. | ||||||
YODA 1 | 448947-81-7 | sc-507361 | 10 mg | $215.00 | ||
Activates Piezo1, indirectly impacting E330034G19Rik through mechanotransduction. YODA1 activates Piezo1, leading to changes in cellular mechanics that influence the expression and function of proteasomal subunits, affecting E330034G19Rik's positive regulation of protein catabolism. | ||||||
Clioquinol | 130-26-7 | sc-201066 sc-201066A | 1 g 5 g | $45.00 $115.00 | 2 | |
Modulates zinc homeostasis, indirectly influencing E330034G19Rik. Clioquinol alters zinc levels, impacting the activity of zinc-dependent proteasomal deubiquitinases and subsequently influencing E330034G19Rik's positive regulation of ubiquitin-dependent protein catabolism. | ||||||